154 related articles for article (PubMed ID: 24585665)
1. Concise review: the bone marrow niche as a target of graft versus host disease.
von Bonin M; Bornhäuser M
Stem Cells; 2014 Jun; 32(6):1420-8. PubMed ID: 24585665
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic Dysfunction during Graft-Versus-Host Disease: A Self-Destructive Process?
Müskens KF; Lindemans CA; Belderbos ME
Cells; 2021 Aug; 10(8):. PubMed ID: 34440819
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
Schwinghammer TL; Bloom EJ
Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
[TBL] [Abstract][Full Text] [Related]
6. Effect of graft-versus-host disease (GVHD) on host hematopoietic progenitor cells is mediated by Fas-Fas ligand interactions but this does not explain the effect of GVHD on donor cells.
Iwasaki T; Hamano T; Saheki K; Kuroiwa T; Kataoka Y; Takemoto Y; Ogata A; Sugihara A; Terada N; Fujimoto J; Kakishita E
Cell Immunol; 1999 Oct; 197(1):30-8. PubMed ID: 10555993
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
Tian Y; Deng YB; Huang YJ; Wang Y
Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
[TBL] [Abstract][Full Text] [Related]
8. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management.
Couriel D; Caldera H; Champlin R; Komanduri K
Cancer; 2004 Nov; 101(9):1936-46. PubMed ID: 15372473
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
[TBL] [Abstract][Full Text] [Related]
10. [Disruption of gut immune system caused by damage of intestinal stem cells and their niche in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.].
Hayase E; Teshima T
Clin Calcium; 2017; 27(6):829-833. PubMed ID: 28536321
[TBL] [Abstract][Full Text] [Related]
11. Graft-versus-host disease: a complex long-term side effect of hematopoietic stem cell transplant.
Barton-Burke M; Dwinell DM; Kafkas L; Lavalley C; Sands H; Proctor C; Johnson E
Oncology (Williston Park); 2008 Oct; 22(11 Suppl Nurse Ed):31-45. PubMed ID: 19856578
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow graft-versus-host disease: early destruction of hematopoietic niche after MHC-mismatched hematopoietic stem cell transplantation.
Shono Y; Ueha S; Wang Y; Abe J; Kurachi M; Matsuno Y; Sugiyama T; Nagasawa T; Imamura M; Matsushima K
Blood; 2010 Jul; 115(26):5401-11. PubMed ID: 20354171
[TBL] [Abstract][Full Text] [Related]
13. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
Michallet M; Dhedin N; Michallet AS
Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
[TBL] [Abstract][Full Text] [Related]
14. Ocular graft-versus-host disease: a review.
Shikari H; Antin JH; Dana R
Surv Ophthalmol; 2013; 58(3):233-51. PubMed ID: 23541042
[TBL] [Abstract][Full Text] [Related]
15. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
Foss FM
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
[TBL] [Abstract][Full Text] [Related]
16. Reduced efficacy of mesenchymal stromal cells in preventing graft-versus-host disease in an in vivo model of haploidentical bone marrow transplant with leukemia.
Oviedo A; Yañez R; Colmenero I; Aldea M; Rubio A; Bueren JA; Lamana ML
Cell Transplant; 2013; 22(8):1381-94. PubMed ID: 23044223
[TBL] [Abstract][Full Text] [Related]
17. Progress and prospects: graft-versus-host disease.
Mastaglio S; Stanghellini MT; Bordignon C; Bondanza A; Ciceri F; Bonini C
Gene Ther; 2010 Nov; 17(11):1309-17. PubMed ID: 20508597
[TBL] [Abstract][Full Text] [Related]
18. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
19. The identification and characteristics of IL-22-producing T cells in acute graft-versus-host disease following allogeneic bone marrow transplantation.
Zhao K; Zhao D; Huang D; Song X; Chen C; Pan B; Wu Q; Cao J; Yao Y; Zeng L; Xu K
Immunobiology; 2013 Dec; 218(12):1505-13. PubMed ID: 23816304
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow graft-versus-host disease: evaluation of its clinical impact on disrupted hematopoiesis after allogeneic hematopoietic stem cell transplantation.
Shono Y; Shiratori S; Kosugi-Kanaya M; Ueha S; Sugita J; Shigematsu A; Kondo T; Hashimoto D; Fujimoto K; Endo T; Nishio M; Hashino S; Matsuno Y; Matsushima K; Tanaka J; Imamura M; Teshima T
Biol Blood Marrow Transplant; 2014 Apr; 20(4):495-500. PubMed ID: 24374213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
